Article
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Clinical colorectal cancer - 1 Sept 2015
Personeni Nicola, Rimassa Lorenza, Verusio Claudio, Barni Sandro, Rubino Luca, Bozzarelli Silvia, Villa Eugenio, Carnaghi Carlo, Tronconi Maria Chiara, Gerardi Chiara, Galli Francesca, Floriani Irene, Destro Annarita, Raschioni Carlotta, Labianca Roberto, Santoro Armando
Abstract excerpt
BACKGROUND: Retrospective studies have suggested that phosphatase and tensin homolog (PTEN) expression might predict the efficacy of cetuximab in patients with KRAS wild-type metastatic colorectal cancer (mCRC). The present study was designed to prospectively evaluate the efficacy of first-line irinotecan, fluorouracil, and folinate (FOLFIRI) plus cetuximab every second week according to PTEN expression. PATIENTS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.